Boehringer Ingelheim advances potential first-in-class IL-11 inhibitor to Phase II Clinical Research in Idiopathic Pulmonary Fibrosis

Notified -

JASCAYD® (nerandomilast) approved in China for the treatment of idiopathic pulmonary fibrosis (IPF)

Notified -

U.S. FDA approves Boehringer’s JASCAYD® (nerandomilast tablets) as first new treatment option for adults with IPF in over a decade

Notified -

Pooled data presented at ERS: nerandomilast monotherapy linked to nominally significant reduction in risk of death in IPF and PPF

Notified -

Global phase III trials demonstrate that nerandomilast slowed lung function decline in IPF and PPF, with similar discontinuation rates to placebo

Notified -

Boehringer’s nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive pulmonary fibrosis

Notified -

Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study

Kinarus Therapeutics Phase 2 KINFAST Covid-19 Clinical

KINFAST is evaluating KIN001 for reduction in severity and duration of Covid-19 symptomsKINFAST is actively enrolling